CJC-1295 (No DAC)
Reported Onset
2–4 weeks
Primary Use
Pulsatile GH release that mimics natural GH secretion patterns.
Dose
100mcg - 200mcg
Frequency
2-3x daily (with Ipamorelin)
Sermorelin
Reported Onset
2–4 weeks
Primary Use
Natural GH stimulation from the pituitary with a well-established safety record.
Dose
200mcg - 500mcg
Frequency
Daily (pre-sleep)
Community Verdict
Both short-acting GHRH analogs; Mod GRF vs original Sermorelin. The community generally selects between CJC-1295 (No DAC) and Sermorelin based on their specific goals and experience. Both compounds are available through physician-supervised protocols at Alukard, where a physician can help determine which is most appropriate for your situation.
Get a Physician-Supervised Protocol for CJC-1295 (No DAC) or Sermorelin at Alukard
Community experiences are a starting point — but a physician-supervised protocol from Alukard gives you pharmaceutical-grade compounds, proper dosing, lab monitoring, and the safety of medical oversight.
MD
Supervised
GMP
Certified
Labs
Monitoring
COA
Verified